SARS
This article was originally published in The Gray Sheet
Executive Summary
Intercept blood system for platelets and red blood cells inactivates the causative agent of severe acute respiratory syndrome, according to Cerus. Intercept, which is approved in Europe, was delayed approval by FDA in June due to an agency request for additional clinical data (1"The Gray Sheet" June 9, 2003, p. 23). No known cases of SARS have yet been reported via blood transfusion, according to the Centers for Disease Control & Prevention...
You may also be interested in...
Baxter/Cerus Pathogen Inactivation PMA Set Back Two Years For More Data
Baxter/Cerus expects the supplemental pivotal trial of its Intercept blood platelet pathogen inactivation system to take 15-18 months to complete
California Bill To Age-Restrict Sales Of Diet Pills Further Along Than Other States’ Legislation
CA, MA and NJ legislatures remain in session with bills active proposing regulations similar to NY law effective 22 April requiring retailers, including online, to ask for proof of age when customers buying consumer health products containing ingredients labeled or promoted for weight loss and bodybuilding benefits appear younger than 18.
CRN Has Standing For Steep Hill To Climb Challenging New York's Age-Restricted Sales
Federal judge finds “misreading of the legislation” in CRN’s argument that state “restricts access based purely on what has been said about the product or its ingredients.” But standing to challenge “means that only CRN is positioned right now to go before the court on behalf of industry,” says CEO Steve Mister.